Edgewise Q3 net loss $25.7M; starts pivotal GRAND CANYON study for EDG-5506

Edgewise Therapeutics, Inc.

2023-Q3 EPS reported -$1.10

Cash and equivalents ~$290M; Q3 net loss $25.7M ($0.41/share) vs $21.5M prior quarter.
Initiated GRAND CANYON, global pivotal study of EDG-5506 in Becker MD, aiming for ~120 patients.
LYNX Phase 2 trial for Duchenne expanding with new cohort; interim data expected H1 2024.
Phase 1 trial of EDG-7500 for hypertrophic cardiomyopathy under way; Phase 1b planned H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Edgewise Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Edgewise Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001157523-23-001700

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.